Table 1.

ORRs, dose-reduction rates, and drug-discontinuation rates of MKIs versus selective RET inhibitors

ORRsDose-reduction rate and drug-discontinuation ratesb
DrugThyroidNSCLCThyroidNSCLC
Vandetanib (Caprelsa)45% (MTC)18%, 53% (Japan)DRR = 81/231 (35%)DRR = 10/19 (53%)
DDR = 28/231 (12%)DDR = 4/19 (21%)
Cabozantinib (Cabometyx/Cometriq)28% (MTC)28%DRR = 169/214 (79%)DRR = 19/26 (73%)
DDR = 35/214 (16%)DDR = 2/26 (8%)
Lenvatinib (Lenvima)36%16%DRR = 35/59 (59%)DRR = 16/25 (64%)
DDR = 14/59 (24%)DDR = 5/25 (20%)
Selpercatiniba (LOXO-292)78% (RET+ thyroid cancer)68%DRR = N/A
59% (MTC)DDR = 9/531 (1.7%)
DRR = N/A
9/531 (1.7%)
Pralsetiniba (BLU-667)56% (MTC)58%DRR = N/A
DDR = 4% (276 patients)
  • Abbreviations: DDR, drug-discontinuation rate; DRR, dose-reduction rate; ORR, objective response rate.

  • aClinical outcomes data on overall survival and progression-free survival emerging as clinical trials are ongoing.

  • bRelatively high dose reduction and discontinuation rates in MKIs due to drug-related adverse events like hypertension, diarrhea, rash, fatigue, hand-foot syndrome, proteinuria, hypopigmentation, QT prolongation, thrombosis, and hemorrhage preclude effective long-term use of MKIs in thyroid cancer.